Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. - Wikidata - wikimedia - TriplyDB

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

http://www.wikidata.org/entity/Q37461136

about

Endothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrier Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease Aβ peptide fibrillar architectures controlled by conformational constraints of the monomer An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease Alzheimer's Aβ peptides with disease-associated N-terminal modifications: influence of isomerisation, truncation and mutation on Cu2+ coordination.Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.Targets for AD treatment: conflicting messages from γ-secretase inhibitors Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms Development of a new DNA vaccine for Alzheimer disease targeting a wide range of aβ species and amyloidogenic peptides Age-related changes of neuron numbers in the frontal cortex of a transgenic mouse model of Alzheimer's disease.Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration.Alzheimer's Disease-Related Protein Expression in the Retina of Octodon degus Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X.Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias.Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits.Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models pGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity.N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody.Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.N-truncated Aβ4-x peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models.Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition.Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy.Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid-β using NMR spectroscopy.Expression of the Alzheimer's Disease Mutations AβPP695sw and PSEN1M146I in Double-Transgenic Göttingen Minipigs.Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer's Disease.Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.

P2860

Q27332086-84D249A9-38BC-4185-99A4-511C237154D4 Q27437619-8710E80E-CBC5-4ADD-AC73-A6542E34BE07 Q28744420-FE39B3BD-D460-43F7-A67A-68AFA5CDDC7A Q30316057-66DA4522-969E-454E-BFDE-03235F5E203C Q30497751-D141406E-BF6C-4F03-805D-B2D8CD8D564E Q30512697-6948A269-E809-4B24-A8A0-BE8053F149C1 Q33624303-645DAF47-393D-4189-A5F9-A4475DE11ECB Q33786789-81182AD3-BA5A-45B4-A4A6-BE745B65DFD2 Q33942884-60353308-477A-46E6-9737-34736BA7F439 Q34348316-5A1D6527-2E11-42BC-8317-4A302BF9F099 Q34481815-2ACA15D1-EEF4-4467-A6FB-6CBE09861C0A Q34575806-86BF6A4F-4757-4A3F-94A2-278DD88AB083 Q34792043-1F7CB456-699E-4E29-A821-2C143E2A2E88 Q34995785-B9FDA99E-D8C0-4BED-B2E8-509623811603 Q35005432-4E2EE011-9EC3-42FF-AF2B-F4100CF2F023 Q35161238-EAC0357A-42F7-4FF4-95DD-05B4FDB37DC5 Q35246412-4C4EC6C1-941C-43B6-A53C-2B8696AA3B62 Q35604177-46033DD5-AEAD-4DF6-A4D3-557307105D46 Q35660682-C8BF3DD6-457C-463F-8600-4D63E24D83E8 Q35679473-675FD136-E7D2-4D66-B15C-EB91AC0A8A5D Q35743990-B3E2AA4B-3CDC-44BD-90FD-FF31B3111F5E Q36340365-739AE07C-3497-47B7-95E8-1F4EC6B6C63B Q36356545-3094E490-323A-4AA3-8E2E-51F755691FDC Q36605288-5F41D8C2-0AD5-44F7-86E2-47E41946A2AE Q36984142-BA470F85-A875-423B-B970-CC6A9F073CD4 Q37043304-382A1FE6-6C26-46C4-B03A-417B39C296AF Q37062829-CFA6C447-2FF5-4903-92B0-0A987CDDF1BB Q37322106-8857EAD7-8081-4D73-BDAE-9B7B9E830381 Q37485472-D47C16D6-B312-4A7F-838D-0B4B7DFA5318 Q38016898-845E87F9-4F9F-4FE7-A2FE-A191CD4F7522 Q38118901-C9630698-3806-4515-9774-8FCE26CA5A7F Q38176899-F109ACEC-1FDD-4406-9CEE-4ABE43673768 Q42278922-2A4DB62F-5684-463F-B9E0-89423DEE8A9D Q46335422-96F59A3C-5049-481B-BC07-4D0DDAC489B5 Q46348872-CE63D436-91F7-486F-8684-CDD19B672E9F Q46902534-D43F2666-2244-444A-A3C6-617390205979 Q48562250-5B90737C-9162-44B3-A339-943592466C69 Q50690253-AB9019E2-6EC6-4B75-AE54-FFFAD3B89ABE Q53311356-8955DEEF-B147-4F3F-BE9B-8A4D38B700C6 Q55021292-5A3AC169-9B6C-4CC8-B68A-D22D4E369EB9

P2860

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

http://www.wikidata.org/entity/Q37461136

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.

@en

Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.

@nl

type

label

Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.

@en

Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.

@nl

prefLabel

Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.

@en

Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.

@nl

P1433

Q37461136-281F66EC-BD3C-4C60-8F22-ACA7A81B8311

P1476

Q37461136-0E05F38E-9612-41A7-BC5C-B734C0F0AD86

P2093

Q37461136-21FE47C8-654F-4CC7-9F4D-BCC3D4FC42DB

Q37461136-2D96A4D4-0F7E-4FEC-8ED2-CEE3B4A50F5F

Q37461136-699BACA1-3430-4074-BB63-C4D92DB1A02C

Q37461136-830A2037-893B-4488-A4AE-133B0C0A8C32

Q37461136-93001967-1B64-49C0-94E4-44658833EE73

Q37461136-AD2DF519-F13A-49EA-BCF7-EA089221CFDD

Q37461136-AE080D2E-E333-4A50-A1AD-951B38437597

Q37461136-B8BB9F8D-6D25-45AC-99BF-52ED552726CF

Q37461136-BBDC7A5E-E133-4943-BA1C-FEBE4AE34242

Q37461136-BC113873-62D4-4530-A630-2EA2F13C7FF8

P2860

Q37461136-030ED301-4575-42C4-BBB5-9570B26BDF9A

Q37461136-0341D8F2-1318-483A-8882-CC584CC6A0D0

Q37461136-0407447A-E4BE-40A1-91FE-E76401203FBA

Q37461136-072169CA-1187-4C06-876D-3512EAFDD576

Q37461136-0CEEE650-67D3-454B-8C6B-FC26E0D6966F

Q37461136-1084916C-232E-4322-8873-00E06B48353A

Q37461136-109B0500-63A3-42A5-A56E-C623EC32D69D

Q37461136-142003F6-3153-4881-A353-47AAA01AC1DE

Q37461136-215CDB41-8B4B-479A-A999-05C79A784D83

Q37461136-23C3A719-58DC-4E7B-BA56-2BEE07ACB2B9

P2888

Q37461136-3575A98B-527B-44F0-8B18-592DAB6CC678

P304

Q37461136-2919F9C9-8073-46EE-8803-7DEE488C09C5

P31

Q37461136-8BD52BB3-7BC8-4C40-B292-9C22530B3014

P356

Q37461136-84F7B5C2-79CA-4088-807C-09036DCD09D8

P433

Q37461136-9FBE9807-AFAC-4874-B6A3-CDBC4FD7B6CD

P478

Q37461136-3E9226C7-EBBB-4D5A-BBC7-90FD572C19CF

P50

Q37461136-1E003A5C-7FD0-4356-8DA2-C1D56678442F

Q37461136-9073B55C-DCF6-42A7-95F8-A7D7DAA1D5F6

P577

Q37461136-37E4D6E3-7B8F-4E8D-B622-009AF35AEC9F

P5875

Q37461136-5CA569EA-B218-4BD1-A4E3-11A1CB2ECB80

P698

Q37461136-932D93B3-38E9-47D5-BAEA-C509953CEDFD

P921

Q37461136-1d8b5940-1b9b-4050-b893-f22837300fec

Q37461136-E5D75F20-D744-46E3-A658-13D523AB474C

P932

Q37461136-D40B4513-A400-44BB-907B-F800214CC277

P356

S00702-009-0314-X

P1433

Journal of Neural Transmission

P1476

Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.

@en

P2093

Andrea Marcello

http://www.w3.org/2001/XMLSchema#string

Anja Harmeier

http://www.w3.org/2001/XMLSchema#string

David L Brody

http://www.w3.org/2001/XMLSchema#string

Hannu Kalimo

http://www.w3.org/2001/XMLSchema#string

Lars Lannfelt

http://www.w3.org/2001/XMLSchema#string

Oliver Wirths

http://www.w3.org/2001/XMLSchema#string

Paul J Lucassen

http://www.w3.org/2001/XMLSchema#string

Sadim Jawhar

http://www.w3.org/2001/XMLSchema#string

Thomas A Bayer

http://www.w3.org/2001/XMLSchema#string

Thomas Esparza

http://www.w3.org/2001/XMLSchema#string

P2860

Amyloid plaque core protein in Alzheimer disease and Down syndrome

Alzheimer's disease: genes, proteins, and therapy

Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.

Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells.

Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions.

The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease.

Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model

Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model

P2888

s00702-009-0314-x

P304

85-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00702-009-0314-X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Martin Ingelsson

P577

2009-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26889402

http://www.w3.org/2001/XMLSchema#string

P698

19823761

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2789212

http://www.w3.org/2001/XMLSchema#string